Literature DB >> 15564505

Localization and characterization of flavivirus envelope glycoprotein cross-reactive epitopes.

Wayne D Crill1, Gwong-Jen J Chang.   

Abstract

The flavivirus E glycoprotein, the primary antigen that induces protective immunity, is essential for membrane fusion and mediates binding to cellular receptors. Human flavivirus infections stimulate virus species-specific as well as flavivirus cross-reactive immune responses. Flavivirus cross-reactive antibodies in human sera create a serious problem for serodiagnosis, especially for secondary flavivirus infections, due to the difficulty of differentiating primary from secondary cross-reactive serum antibodies. The presence of subneutralizing levels of flavivirus cross-reactive serum antibodies may result in a dramatic increase in the severity of secondary flavivirus infections via antibody-dependent enhancement. An understanding of flavivirus E-glycoprotein cross-reactive epitopes is therefore critical for improving public health responses to these serious diseases. We identified six E-glycoprotein residues that are incorporated into three distinct flavivirus cross-reactive epitopes. Two of these epitopes which are recognized by distinct monoclonal antibodies contain overlapping continuous residues located within the highly conserved fusion peptide. The third epitope consists of discontinuous residues that are structurally related to the strictly conserved tryptophan at dengue virus serotype 2 E-glycoprotein position 231.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15564505      PMCID: PMC533943          DOI: 10.1128/JVI.78.24.13975-13986.2004

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  50 in total

Review 1.  Antibody-dependent enhancement of viral infection: molecular mechanisms and in vivo implications.

Authors:  Ayato Takada; Yoshihiro Kawaoka
Journal:  Rev Med Virol       Date:  2003 Nov-Dec       Impact factor: 6.989

2.  X-ray snapshots of the maturation of an antibody response to a protein antigen.

Authors:  Yili Li; Hongmin Li; Feng Yang; Sandra J Smith-Gill; Roy A Mariuzza
Journal:  Nat Struct Biol       Date:  2003-06

3.  Questions on viral population biology to complete dengue puzzle.

Authors:  Christine Chevillon; Anna-Bella Failloux
Journal:  Trends Microbiol       Date:  2003-09       Impact factor: 17.079

Review 4.  Recent advancement in flavivirus vaccine development.

Authors:  Gwong-Jen J Chang; Goro Kuno; David E Purdy; Brent S Davis
Journal:  Expert Rev Vaccines       Date:  2004-04       Impact factor: 5.217

5.  Epitopic analysis of antigenic determinants on the surface of dengue-2 virions using monoclonal antibodies.

Authors:  E A Henchal; J M McCown; D S Burke; M C Seguin; W E Brandt
Journal:  Am J Trop Med Hyg       Date:  1985-01       Impact factor: 2.345

6.  Protection against West Nile virus induced by a previous injection with dengue virus.

Authors:  W H Price; I S Thind
Journal:  Am J Epidemiol       Date:  1971-12       Impact factor: 4.897

7.  Identification of distinct antigenic determinants on dengue-2 virus using monoclonal antibodies.

Authors:  M K Gentry; E A Henchal; J M McCown; W E Brandt; J M Dalrymple
Journal:  Am J Trop Med Hyg       Date:  1982-05       Impact factor: 2.345

8.  Nucleotide sequence of yellow fever virus: implications for flavivirus gene expression and evolution.

Authors:  C M Rice; E M Lenches; S R Eddy; S J Shin; R L Sheets; J H Strauss
Journal:  Science       Date:  1985-08-23       Impact factor: 47.728

9.  Chimeric tick-borne encephalitis and dengue type 4 viruses: effects of mutations on neurovirulence in mice.

Authors:  A G Pletnev; M Bray; C J Lai
Journal:  J Virol       Date:  1993-08       Impact factor: 5.103

10.  Antibody-dependent enhancement of Murray Valley encephalitis virus virulence in mice.

Authors:  M J Wallace; D W Smith; A K Broom; J S Mackenzie; R A Hall; G R Shellam; P C McMinn
Journal:  J Gen Virol       Date:  2003-07       Impact factor: 3.891

View more
  149 in total

1.  Antibodies targeting dengue virus envelope domain III are not required for serotype-specific protection or prevention of enhancement in vivo.

Authors:  Katherine L Williams; Wahala M P B Wahala; Susana Orozco; Aravinda M de Silva; Eva Harris
Journal:  Virology       Date:  2012-04-25       Impact factor: 3.616

2.  Development of human-murine chimeric immunoglobulin G for use in the serological detection of human flavivirus and alphavirus antibodies.

Authors:  Brett A Thibodeaux; Amanda N Panella; John T Roehrig
Journal:  Clin Vaccine Immunol       Date:  2010-08-25

3.  Immunodominance and functional activities of antibody responses to inactivated West Nile virus and recombinant subunit vaccines in mice.

Authors:  Juergen Zlatkovic; Karin Stiasny; Franz X Heinz
Journal:  J Virol       Date:  2010-12-08       Impact factor: 5.103

4.  Genome-wide patterns of intrahuman dengue virus diversity reveal associations with viral phylogenetic clade and interhost diversity.

Authors:  Poornima Parameswaran; Patrick Charlebois; Yolanda Tellez; Andrea Nunez; Elizabeth M Ryan; Christine M Malboeuf; Joshua Z Levin; Niall J Lennon; Angel Balmaseda; Eva Harris; Matthew R Henn
Journal:  J Virol       Date:  2012-05-30       Impact factor: 5.103

5.  Recombinant dengue type 2 viruses with altered e protein domain III epitopes are efficiently neutralized by human immune sera.

Authors:  Wahala M P B Wahala; Claire Huang; Siritorn Butrapet; Laura J White; Aravinda M de Silva
Journal:  J Virol       Date:  2012-01-25       Impact factor: 5.103

6.  Transposon Mutagenesis of the Zika Virus Genome Highlights Regions Essential for RNA Replication and Restricted for Immune Evasion.

Authors:  Benjamin O Fulton; David Sachs; Megan C Schwarz; Peter Palese; Matthew J Evans
Journal:  J Virol       Date:  2017-07-12       Impact factor: 5.103

7.  Induction of epitope-specific neutralizing antibodies against West Nile virus.

Authors:  Theodore Oliphant; Grant E Nybakken; S Kyle Austin; Qing Xu; Jonathan Bramson; Mark Loeb; Mark Throsby; Daved H Fremont; Theodore C Pierson; Michael S Diamond
Journal:  J Virol       Date:  2007-08-22       Impact factor: 5.103

8.  Differentiation of West Nile and St. Louis encephalitis virus infections by use of noninfectious virus-like particles with reduced cross-reactivity.

Authors:  Jill A Roberson; Wayne D Crill; Gwong-Jen J Chang
Journal:  J Clin Microbiol       Date:  2007-08-22       Impact factor: 5.948

Review 9.  Zika Virus: Immunity and Vaccine Development.

Authors:  Theodore C Pierson; Barney S Graham
Journal:  Cell       Date:  2016-09-29       Impact factor: 41.582

10.  Development of a human-murine chimeric immunoglobulin M antibody for use in the serological detection of human flavivirus antibodies.

Authors:  Brett A Thibodeaux; John T Roehrig
Journal:  Clin Vaccine Immunol       Date:  2009-03-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.